EA201990915A1 - Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения - Google Patents

Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения

Info

Publication number
EA201990915A1
EA201990915A1 EA201990915A EA201990915A EA201990915A1 EA 201990915 A1 EA201990915 A1 EA 201990915A1 EA 201990915 A EA201990915 A EA 201990915A EA 201990915 A EA201990915 A EA 201990915A EA 201990915 A1 EA201990915 A1 EA 201990915A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
hydroxytriptamine
application
new modulators
modulators
Prior art date
Application number
EA201990915A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201990915A1 publication Critical patent/EA201990915A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
EA201990915A 2016-11-15 2017-11-15 Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения EA201990915A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422344P 2016-11-15 2016-11-15
PCT/US2017/061677 WO2018093818A1 (en) 2016-11-15 2017-11-15 Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Publications (1)

Publication Number Publication Date
EA201990915A1 true EA201990915A1 (ru) 2019-11-29

Family

ID=62146107

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990915A EA201990915A1 (ru) 2016-11-15 2017-11-15 Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения

Country Status (14)

Country Link
US (4) US10858368B2 (OSRAM)
EP (1) EP3541790B1 (OSRAM)
JP (3) JP7107955B2 (OSRAM)
KR (1) KR102590403B1 (OSRAM)
CN (2) CN119977980A (OSRAM)
AU (3) AU2017361078B2 (OSRAM)
CA (1) CA3043319A1 (OSRAM)
CL (1) CL2019001329A1 (OSRAM)
EA (1) EA201990915A1 (OSRAM)
IL (3) IL309982A (OSRAM)
MX (2) MX394746B (OSRAM)
UA (1) UA125631C2 (OSRAM)
WO (1) WO2018093818A1 (OSRAM)
ZA (1) ZA202105774B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164756A1 (en) 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
CA3043319A1 (en) 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
US11220505B2 (en) * 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
MA49019A (fr) * 2017-03-21 2020-02-05 Univ Temple Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
CN112437768B (zh) * 2018-05-11 2025-06-24 英联邦高等教育系统坦普尔大学 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法
JP2023501576A (ja) * 2019-11-13 2023-01-18 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクトンおよびその使用方法
US20230002383A1 (en) * 2019-11-13 2023-01-05 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
TW202328148A (zh) * 2021-09-22 2023-07-16 日商塩野義製藥股份有限公司 具有血清素受體結合活性之螺雜環衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040064499A1 (en) 2002-09-26 2004-04-01 Kasra Kasravi Method and system for active knowledge management
JP2006516604A (ja) 2003-01-31 2006-07-06 ファイザー・プロダクツ・インク ５ｈｔ７アンタゴニストおよび逆アゴニスト
RU2006129464A (ru) 2004-01-16 2008-02-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы
EP1928461B1 (en) 2005-08-04 2012-01-04 Janssen Pharmaceutica NV Pyrimidine compounds as serotonin receptor modulators
EP1875899A1 (en) 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
ES2380756T3 (es) 2007-10-12 2012-05-18 Eli Lilly And Company Antagonistas del receptor 5-HT7
US7902091B2 (en) 2008-08-13 2011-03-08 Varian Semiconductor Equipment Associates, Inc. Cleaving of substrates
ES2459322T3 (es) 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
WO2010069390A1 (en) 2008-12-19 2010-06-24 Nokia Siemens Networks Oy Method and device for data processing in an udwdm network and communication system comprising such device
US8637263B1 (en) * 2010-10-14 2014-01-28 Epiomed Therapeutics, Inc. Assay for determination of compounds having anti-emetic activity
US20130287705A1 (en) 2010-11-03 2013-10-31 Mcmaster University Method of treating mucosal inflammation
WO2013154513A1 (en) * 2012-04-04 2013-10-17 Mi̇lli̇ Savunma Bakanliği The use of 5-ht7 receptor antagonists including some atypical antipsychotics as antipruritic agents
US9464062B2 (en) 2012-11-28 2016-10-11 Temple University—Of the Commonwealth System of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
WO2014164756A1 (en) * 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CA3043319A1 (en) 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Modulators of the 5-hydroxytryptamine receptor 7 and their method of use
MA49019A (fr) 2017-03-21 2020-02-05 Univ Temple Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
US11220505B2 (en) 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
CN112437768B (zh) 2018-05-11 2025-06-24 英联邦高等教育系统坦普尔大学 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法
JP2023501576A (ja) * 2019-11-13 2023-01-18 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクトンおよびその使用方法

Also Published As

Publication number Publication date
CN119977980A (zh) 2025-05-13
JP7107955B2 (ja) 2022-07-27
IL291029B2 (en) 2024-06-01
CL2019001329A1 (es) 2019-08-30
CA3043319A1 (en) 2018-05-24
IL291029B1 (en) 2024-02-01
EP3541790A1 (en) 2019-09-25
KR20190097006A (ko) 2019-08-20
EP3541790C0 (en) 2025-09-03
MX2019005603A (es) 2019-10-14
ZA202105774B (en) 2022-07-27
JP2019535825A (ja) 2019-12-12
US20210238189A1 (en) 2021-08-05
US11319327B2 (en) 2022-05-03
AU2022202240A1 (en) 2022-04-28
IL266483A (en) 2019-07-31
WO2018093818A1 (en) 2018-05-24
IL309982A (en) 2024-03-01
KR102590403B1 (ko) 2023-10-16
EP3541790A4 (en) 2020-06-17
EP3541790B1 (en) 2025-09-03
CN110177776B (zh) 2025-02-28
KR20230148384A (ko) 2023-10-24
AU2024204240A1 (en) 2024-07-11
US20250282790A1 (en) 2025-09-11
MX2022009907A (es) 2022-08-25
IL291029A (en) 2022-05-01
JP2022132444A (ja) 2022-09-08
US20230112888A1 (en) 2023-04-13
MX394746B (es) 2025-03-24
IL266483B (en) 2022-04-01
US10858368B2 (en) 2020-12-08
UA125631C2 (uk) 2022-05-04
US20190367528A1 (en) 2019-12-05
BR112019009908A2 (pt) 2019-08-13
JP7482948B2 (ja) 2024-05-14
AU2017361078A1 (en) 2019-05-30
US12338247B2 (en) 2025-06-24
AU2017361078B2 (en) 2022-01-06
JP2024091996A (ja) 2024-07-05
AU2022202240B2 (en) 2024-03-21
CN110177776A (zh) 2019-08-27

Similar Documents

Publication Publication Date Title
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201890111A1 (ru) Замещенные производные оксопиридина
MX389627B (es) Inhibidores de la magl.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA202092328A1 (ru) Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX378806B (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
CL2016002422A1 (es) Cromeno y 1, 1a,2,7b-tetrahidrociclopropa[c]cromeno piridopirazinadionas como moduladores de gamma-secretasas.
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
MX381224B (es) Potentes moduladores de gamma-secretasa.
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MA50163A (fr) Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité